Doximity, Inc. (BVMF:D2OC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 31.89B -50.4% |
| Revenue (ttm) | 3.43B +6.5% |
| Net Income | 723.71M -44.8% |
| EPS | 0.66 -42.3% |
| Shares Out | n/a |
| PE Ratio | 44.27 |
| Forward PE | 21.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,800 |
| Open | 29.31 |
| Previous Close | 31.29 |
| Day's Range | 29.31 - 29.31 |
| 52-Week Range | 14.36 - 55.98 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Doximity
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools... [Read more]
Financial Performance
In fiscal year 2026, Doximity's revenue was $644.86 million, an increase of 13.05% compared to the previous year's $570.40 million. Earnings were $196.05 million, a decrease of -12.16%.
Financial numbers in USD Financial StatementsNews
Doximity price target raised to $40 from $36 at Canaccord
Canaccord raised the firm’s price target on Doximity (DOCS) to $40 from $36 and keeps a Buy rating on the shares. The firm said Q2 results were solid and beleive…
Doximity price target raised to $30 from $29 at Jefferies
Jefferies analyst Brian Tanquilut raised the firm’s price target on Doximity (DOCS) to $30 from $29 and keeps a Hold rating on the shares following a “good” quarter. Doximity is…
Doximity price target raised to $34 from $28 at RBC Capital
RBC Capital analyst Ryan Halsted raised the firm’s price target on Doximity (DOCS) to $34 from $28 and keeps an Outperform rating on the shares. The company delivered a clean…
Doximity price target raised to $40 from $36 at Canaccord
Canaccord raised the firm’s price target on Doximity (DOCS) to $40 from $36 and keeps a Buy rating on the shares. The fim said 2QFY27 results were solid, with revenue…
Doximity Earnings Call Transcript: Q2 2027
Q2 revenue rose 4% YoY to $174.5 million, while adjusted EBITDA reached $89 million at a 51% margin. AI Search bookings and clinician engagement accelerated, and FY 2027 revenue guidance was raised; management expects a gradual AI Search revenue ramp.
Doximity Slides: Q2 2027
Doximity has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 5, 2026.
Doximity Prepared remarks: Q2 2027
Doximity filed a regulatory document on November 5, 2026 disclosing important business information.
Doximity Quarterly report: Q2 2027
Doximity has published its Q2 2027 quarterly earnings report on November 5, 2026.
Doximity Earnings release: Q2 2027
Doximity released its Q2 2027 earnings on November 5, 2026, summarizing the period's financial results.
Doximity reports Q2 EPS 36c, consensus 35c
Reports Q2 revenue $174.5M, consensus $170.3M. “We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin,” said Jeff Tangney, co-fou...
Doximity sees Q3 revenue $195M-$196M, consensus $193.37M
Sees Q4 adjusted EBITDA $102.5M-$103.5M
Doximity sees FY27 revenue $678M-$683M, consensus $675.6M
Sees Fy27 adjusted EBITDA $317M-$325M
Doximity Announces Fiscal 2027 Second Quarter Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, ...
Doximity launches DoseCheck, an additional safety layer in Doximity Ask
Doximity (DOCS) has launched DoseCheck, a free additional safety layer in Doximity Ask that instantly checks every AI-generated medication dosing claim against a structured drug database to reduce tre...
Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has launched DoseCheck, a free additional safety layer in Doximity Ask that in...
What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Doximity, Inc. failed to disclose key facts to investors from August 8, 2024 through May 13, 2026; lead plaintiff deadline is November 16, 2026 BENSALEM TOWNSHIP, Pa., Oct. 28, 2026 /PRNe...
What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Doximity, Inc. made misleading statements to investors from August 8, 2024 to May 13, 2026; lead plaintiff motions are due November 16, 2026 LOS ANGELES, Oct. 27, 2026 /PRNewswire/ -- ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Doximity, Inc. Lawsuit - DOCS
Doximity reported "record engagement" using metrics of its own design, yet the securities action contends its disclosures omitted the market share erosion and light-engagement advertising methods that...
Kaplan Fox Alerts Doximity, Inc. (DOCS) Investors to an Approaching Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Kaplan Fox Reminds Doximity, Inc. (DOCS) Investors to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Doximity, Wolters Kluwer partner to bring UpToDate to Doximity Ask
Doximity (DOCS) and Wolters Kluwer Health (WTKWY) announced that UpToDate’s trusted, evidence-based, clinical content will be accessible directly within Doximity’s fast-growing AI clinical decision su...
Doximity and Wolters Kluwer Sign Partnership to Bring UpToDate to Doximity Ask
SAN FRANCISCO & WALTHAM, Mass.--(BUSINESS WIRE)--Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, and Wolters Kluwer Health, today announced that UpToDate's trusted,...
Doximity price target raised to $23 from $20 at BofA
BofA raised the firm’s price target on Doximity (DOCS) to $23 from $20 and keeps an Underperform rating on the shares. The firm’s quarterly survey on pharma advertising was “surprisingly…
Kaplan Fox Notifies Investors of Doximity, Inc. (DOCS) of the Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...
Kaplan Fox Urges Doximity, Inc. (DOCS) Investors to Contact the Firm Before the Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: D...